Mumbai-Ahmedabad Bullet Train BIG Update, project likely to be completed by..., top speed to be...
Structural work is complete at six of eight planned stations in Gujarat, with track bed construction advancing along 143 km of the viaduct. More than 3 lakh noise barriers have been installed over a 150 km stretch to minimize operational noise. According to the reports, the river crossings have also seen rapid progress. Bridges across 14 rivers, including Par, Purna, Mindhola, and Ambika, are now completed. Additionally, seven steel bridges and five PSC (pre-stressed concrete) bridges have been built, boosting overall connectivity.
Progress has been made on the tunnel work between Mumbai's Bandra Kurla Complex (BKC) and Shilphata. Approximately 3.3 km of tunneling has been completed using the New Austrian Tunneling Method (NATM). Additionally, the Vikhroli and Sawli shafts have reached significant depths of 56 meters and 39 meters, respectively. In Maharashtra's Palghar district, seven mountain tunnels are currently under construction.
Work on Mumbai's bullet train station is gaining pace. Excavation for the base slab is around 75% complete, with 25,000 cubic meters of concrete already poured. Meanwhile, overhead equipment mast (OHE) installation has begun between Surat and Bilimora stations, covering approximately 2 km of viaduct.
With this steady pace, the Mumbai-Ahmedabad Bullet Train — India's first — is on course to redefine travel with speed, efficiency, and world-class infrastructure.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
10 hours ago
- Mint
As TCS loses shine, investors place hopes on Infosys, HCLTech
Three straight quarters of falling revenues at Tata Consultancy Services Ltd could prompt investors to prefer shares of Infosys Ltd and HCL Technologies Ltd, even as India's largestinformation technology services firm trades at a discount to the other two. The TCS stock is currently trading at 24.6 times the company's forward price-earnings while Infosys and HCLTech, India's second- and third-largest IT services firms, are trading at 25.9 and 36.2 times their earnings, respectively, according to Bloomberg data. TCS last traded at a discount to Infosys in January 2022, and was valued cheaper than HCL Technologies in September 2010. The price-to-earnings (P/E) ratio is arrived at after dividing the current value of a stock by its annual earnings and a key metric to measure how expensive a stock is. TCS shares have declined by more than 20% this year on NSE, while Infosys was down about 15% and HCLTech about 14.5% as of 11 July. The Nifty IT index was down about 13%. 'TCS's edge over peers has reduced in the last several years driven by better execution of peers who have caught up on large/mega deal structuring and digital competencies," said Kotak Institutional Equities analysts Kawaljeet Saluja, Sathishkumar S., and Vamshi Krishna in a note dated 10 July. 'Competitive intensity has increased with ambitious mid-tier and renewed push from Tier-1," the Kotak analysts added. At the heart of TCS losing its premium to its smaller rivals is the Mumbai-based company's underperformance over the previous three quarters. On 10 July, TCS registered its slowest start to a fiscal year in five years as the company reported its earnings for the April-June quarter. TCS's dollarrevenue in the financial first quarter for 2025-26 slipped 0.59% from the preceding three months, following a 0.98% sequential fall in the January-March quarter and a 1.7% decline in the October-December period. Infosys's revenue declined 4.23% sequentially in the March quarter, after rising 0.92% sequentially in the three months to end-December. HCLTech's revenue fell 1% sequentially in the fourth quarter after growing 2.55% in the third quarter. HCL Technologies will declare its first-quarter earnings on 14 July, and Infosys on 23 July. 'Higher expectations for Infy, HCLTech' TCS, under K. Krithivasan who took charge as chief executive on 1 June 2023, was not able to win enough mega contracts (deals valued at more than $1 billion) in 2024-25 to drive growth, according to analysts. 'TCS last announced a mega deal excluding significant inter-group transactions (such as BSNL and JLR) and Diligenta platform (such as Aviva and NEST) where competition is low, in 2022. From then to now, competition has announced multiple mega deals," the Kotak analysts said in their note. Mint reported on 10 July that while much of TCS's recent growth was driven by Bharat Sanchar Nigam Ltd, the IT outsourcer would not get much revenue from the state-run telecom company in future. BSNL had awarded a $1.83 billion contract to TCS two years ago. As for JLR, or Jaguar Land Rover, TCS in 2023 won an £800-million order from Tata Motors Ltd's British subsidiary to revamp its IT systems. But JLR's declining sales could curb discretionary spending by the company. Abhishek Kumar, equity analyst at JM Financial, said investors' bets on Infosys and HCLTech were on account of the companies' better growth in the previous two years and higher growth prospects. 'The premium is a reflection of investors' higher growth expectations for HCLTech and Infosys versus TCS," said Kumar. TCS's revenue grew 3.78% in 2024-25, slower than Infosys's 3.85% and HCL Technologies's 4.3% pace. In FY24, TCS's 4.1% revenue growth lagged HCLTech's 5.4% but was better than Infosys's 1.9%. Natarajan Chandrasekaran, chair of Tata Sons, which owns 71.77% in TCS, recognising TCS's challenges, recently appointed two Tata Group executives to assist Krithivasan in steering the company. On 10 April, Aarthi Subramanian was appointed TCS's chief operating officer, and Mangesh Sathe as chief strategy officer. 'Growth remains elusive for TCS' Investors in Indian IT services companies are also taking cues from uncertainties caused by the rapid adoption of generative artificial intelligence (Gen AI) across industries and smaller IT companies being able to strike competitive large deals. In TCS's annual report for FY25, Krithivasan said clients were increasingly shifting focus from a use case-based approach to return on investment-led scaling of AI, and that the appointments of Subramanian and Sathe were driven by 'the industry shifts led by AI". However, Motilal Oswal analysts said 'growth for TCS remains elusive". 'It is now clear that productivity benefits are being promised as a part of most deals, potentially dragging future revenues for the (IT) industry. In most tech cycles, however, a declining legacy business is offset by a growing new-age business. This kicker is missing in this cycle, putting further pressure on growth," Motilal Oswal analysts Abhishek Pathak, Keval Bhagat and Tushar Dhonde wrote in a note dated 10 July. TCS ended June with an operating margin of 24.5%, higher than Infosys's 21% and HCLTech's 17.9%. The company ended Friday, 11 July, with a market capitalisation of $137.6 billion, making it India's most-valued IT services firm. Infosys and HCLTech are valued at about $77.2 billion and $51.7 billion, respectively. JM Financial's Kumar expects a reversal in the valuation disconnect among the country's three largest IT services firms. 'Deal wins are far more consistent for TCS as compared with peers and the discount should go away once macroeconomic uncertainties lift and growth converges," said Kumar. TCS reported an order book with a total contract value of $9.4 billion for the first quarter of 2025-26, up 13% from the corresponding year-ago period.
Economic Times
10 hours ago
- Economic Times
Cipla eyes entry into India's weight management market amid rising demand and global competition
Synopsis Cipla is set to enter India's weight management market, addressing the increasing demand for obesity solutions, while also strengthening its central nervous system portfolio through strategic in-licensing deals and acquisitions, particularly in ADHD and Parkinson's disease. The company is also focusing on innovation-led solutions to combat antimicrobial resistance and aims to be a global, patient-centric healthcare leader. Agencies Representative image Drug major Cipla is preparing to foray into the weight management segment in India, its MD and global CEO Umang Vohra has Mumbai-based firm is also strengthening its presence in the central nervous system (CNS) therapeutic area, he stated in his address to shareholders in the company's Annual Report for 2024-25."Our efforts are rooted in understanding patient needs, reducing stigma, and delivering differentiated therapies for niche is emerging as a priority area for Cipla. With a clear strategic intent, we are preparing to enter the weight management segment in India, aiming to address the rising demand for effective obesity solutions," Vohra domestic drug firms are developing drugs for weight loss to capitalise on the growing market for obesity and diabetes drugmaker Eli Lilly & Co has already launched its anti-obesity drug Mounjaro in the country. Danish firm Novo Nordisk has also launched its anti-obesity drug Wegovy, indicated for both long-term chronic weight management and reduction in risk of major adverse cardiovascular the CNS segment, Cipla has successfully in-licensed Sanofi's India CNS product range, including Frisium, a leading brand in the anti-epileptic category, Vohra informed shareholders."Building on this momentum, we aim to pursue similar in-licensing deals or acquisitions in niche indications of attention deficit hyperactivity disorder (ADHD) and Parkinson's disease," he company is equally committed to addressing the global crisis of antimicrobial resistance (AMR), he added."Our AMR portfolio is evolving from volume-based to innovation-led, with four novel products in development," Vohra noted that the company's ambition is to be a global, innovation-led, patient-centric healthcare company that creates long-term value through science, empathy, and sustainability."We will continue to invest in big brands, strategic alliances, digital infrastructure, and next-generation therapies, while remaining rooted in our founding values of care and compassion," Vohra stated. Cipla's consolidated revenue stood at Rs 27,548 crore in FY25. Its consolidated net profit rose to Rs 5,272 crore during the period.
India.com
11 hours ago
- India.com
This company shares to be in focus as board approves conversion 29,66,220 Warrants
ओमांश इंटरप्राइजेज लिमिटेड का शेयर बना रहा मालामाल Shares of Man Infraconstruction Ltd, the Mumbai-based infrastructure and real estate company, are expected to be in the spotlight on Monday, 14 July, after the company announced a preferential allotment of 29.66 lakh equity shares through the conversion of warrants, amounting to ₹34.48 crore. Details of the Allotment The allotment, approved by the board's Allotment Committee on 11 July 2025, follows the exercise of rights by warrant holders who opted to convert their holdings into equity shares. Each warrant was converted at ₹116.25, which represents 75 per cent of the total issue price of ₹155 per warrant. The remaining 25 per cent was presumably paid at the time of initial issuance. Equity Share Details The equity shares, having a face value of ₹2 each, will rank pari-passu with the company's existing equity shares in all respects — including dividend eligibility and voting rights. Share Capital Now at ₹77.56 Crore Following this allotment, the subscribed and paid-up share capital of Man Infraconstruction has increased from Rs 76.96 crore to Rs 77.56 crore, comprising over 38.77 crore equity shares. The company also revealed that 1.85 crore convertible warrants remain outstanding, which can be converted into equity within 18 months from the original allotment date, with a further payment of Rs 116.25 per warrant. The funds raised through the warrant conversion are likely to bolster the company's balance sheet and working capital, given the capital-intensive nature of its business which spans engineering, procurement and construction (EPC) in ports, real estate, and urban infrastructure. Man Infraconstruction has emerged as a multibagger stock, posting a remarkable 1384.11 per cent return over the past five years. This makes it one of the standout performers in India's mid-cap real estate space. Despite some short-term volatility — the stock fell 1.57 per cent to close at ₹182.10 on the BSE on Friday — it remains up 25.28 per cent for the current quarter. The stock, however, has corrected 9.54 per cent over the past year, possibly due to profit-booking and broader market weakness.
